milrinone has been researched along with Postoperative Complications in 43 studies
Postoperative Complications: Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to evaluate the effect of preoperative inhalation of milrinone on cardiopulmonary bypass (CPB)-related inflammation." | 9.16 | Preoperative inhalation of milrinone attenuates inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass. ( Gong, M; Lin, XZ; Lu, GT; Zheng, LJ, 2012) |
| "The phosphodiesterase inhibitor milrinone is usually preferred in patients with pulmonary hypertension and myocardial dysfunction after cardiopulmonary bypass." | 9.12 | Effects of low-dose milrinone on weaning from cardiopulmonary bypass and after in patients with mitral stenosis and pulmonary hypertension. ( Canik, S; Goksel, O; Issever, H; Oztekin, DS; Oztekin, I; Yazici, S, 2007) |
| "There is insufficient evidence of the effectiveness of prophylactic milrinone in preventing death or low cardiac output syndrome in children undergoing surgery for congenital heart disease, compared to placebo." | 8.91 | Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease. ( Burkhardt, BE; Rücker, G; Stiller, B, 2015) |
| " The aim of this study was to retrospectively evaluate the effect of inhaled milrinone versus inhaled iloprost in patients with persistent pulmonary hypertension following discontinuation of CPB." | 7.85 | A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension. ( Antoniou, T; Leontiadis, E; Perreas, K; Rellia, P; Thanopoulos, A; Theodoraki, K; Zarkalis, D, 2017) |
| "We conclude that milrinone is effective in the management of pulmonary hypertension following CPB in children who underwent TOF repair." | 7.70 | Effect of milrinone on postbypass pulmonary hypertension in children after tetralogy of Fallot repair. ( Chow, LH; Chu, CC; Lee, TY; Lin, SM; New, SH; Ting, CK; Tsai, SK; Tsou, MY, 2000) |
| "Milrinone use is an independent risk factor for postoperative AF after elective cardiac surgery." | 6.73 | Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. ( Ball, SK; Brown, NJ; Byrne, JG; Fleming, GA; Greelish, JP; Hoff, SJ; Murray, KT; Petracek, MR; Pretorius, M; Yu, C, 2008) |
| "Secondary pulmonary hypertension is a frequent condition after heart valve surgery." | 5.36 | Combined usage of inhaled and intravenous milrinone in pulmonary hypertension after heart valve surgery. ( Bulat, C; Carev, M; Husedzinović, I; Jercić, A; Karanović, N; Letica, D; Lojpur, M; Marovih, Z; Nenadić, D, 2010) |
| "The purpose of this study was to evaluate the effect of preoperative inhalation of milrinone on cardiopulmonary bypass (CPB)-related inflammation." | 5.16 | Preoperative inhalation of milrinone attenuates inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass. ( Gong, M; Lin, XZ; Lu, GT; Zheng, LJ, 2012) |
| "The phosphodiesterase inhibitor milrinone is usually preferred in patients with pulmonary hypertension and myocardial dysfunction after cardiopulmonary bypass." | 5.12 | Effects of low-dose milrinone on weaning from cardiopulmonary bypass and after in patients with mitral stenosis and pulmonary hypertension. ( Canik, S; Goksel, O; Issever, H; Oztekin, DS; Oztekin, I; Yazici, S, 2007) |
| "There is insufficient evidence of the effectiveness of prophylactic milrinone in preventing death or low cardiac output syndrome in children undergoing surgery for congenital heart disease, compared to placebo." | 4.91 | Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease. ( Burkhardt, BE; Rücker, G; Stiller, B, 2015) |
| "We reviewed the charts of eight adult patients with postoperative pulmonary hypertension who received oral sildenafil (25 to 50 mg) to facilitate weaning of IV (milrinone, nitroglycerine, and sodium nitroprusside) and inhaled (nitric oxide) pulmonary vasodilators." | 4.82 | Oral sildenafil reduces pulmonary hypertension after cardiac surgery. ( Beaver, TM; Hess, PJ; Klodell, CT; Lobato, EB; Martin, TD; Staples, ED; Trachte, AL; Urdaneta, F, 2005) |
| "Population pharmacokinetic modeling and simulations suggest a slow loading dose followed by maintenance infusion to reach therapeutic milrinone plasma concentrations within the timeframe of the postligation cardiac syndrome." | 3.91 | Population Pharmacokinetics and Dosing of Milrinone After Patent Ductus Arteriosus Ligation in Preterm Infants. ( Hallik, M; Ilmoja, ML; Jalas, T; Kipper, K; Metsvaht, T; Raidmäe, M; Standing, JF; Starkopf, J; Takkis, K; Tasa, T; Uibo, K; Veigure, R, 2019) |
| " The aim of this study was to retrospectively evaluate the effect of inhaled milrinone versus inhaled iloprost in patients with persistent pulmonary hypertension following discontinuation of CPB." | 3.85 | A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension. ( Antoniou, T; Leontiadis, E; Perreas, K; Rellia, P; Thanopoulos, A; Theodoraki, K; Zarkalis, D, 2017) |
| " We examined the effects of vasopressin (arginine vasopressin [AVP]) on acute kidney injury (AKI) in postoperative period." | 3.81 | Intraoperative administration of vasopressin during coronary artery bypass surgery is associated with acute postoperative kidney injury. ( Arora, P; Davari-Farid, S; Li, CM; Nader, ND; Porhomayon, J; Pourafkari, L, 2015) |
| " Preoperative milrinone use might decrease the risk of severe right ventricular failure requiring additional RVAD insertion and improve postimplantation survival in children with advanced heart failure." | 3.79 | Factors associated with the need of biventricular mechanical circulatory support in children with advanced heart failure. ( Fan, Y; Franz, N; Hetzer, R; Huebler, M; Miera, O; Qian, GS; Weng, YG; Zhang, AM, 2013) |
| "We conclude that milrinone is effective in the management of pulmonary hypertension following CPB in children who underwent TOF repair." | 3.70 | Effect of milrinone on postbypass pulmonary hypertension in children after tetralogy of Fallot repair. ( Chow, LH; Chu, CC; Lee, TY; Lin, SM; New, SH; Ting, CK; Tsai, SK; Tsou, MY, 2000) |
| "Hemodynamic and biochemical variables were recorded in 29 status 1 men with symptoms of severe congestive heart failure, who received continuous intravenous milrinone alone (group 1, n = 21) or in combination with inotropic agents (group 2, n = 8) while awaiting heart transplantation." | 3.70 | Milrinone for long-term pharmacologic support of the status 1 heart transplant candidates. ( Canver, CC; Chanda, J, 2000) |
| "Milrinone use is an independent risk factor for postoperative AF after elective cardiac surgery." | 2.73 | Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. ( Ball, SK; Brown, NJ; Byrne, JG; Fleming, GA; Greelish, JP; Hoff, SJ; Murray, KT; Petracek, MR; Pretorius, M; Yu, C, 2008) |
| "Iloprost was administered during weaning from cardiopulmonary bypass (CPB)." | 2.73 | Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. ( Autschbach, R; Buhre, W; de Waal, EE; Flier, S; Metzelder, S; Rex, S; Rossaint, R; Schaelte, G, 2008) |
| "Milrinone was administrated just after the aortic declamping during CPB." | 2.69 | [The effect of milrinone administrated before weaning from cardiopulmonary bypass in adult cardiac surgery]. ( Hamawaki, M; Hibino, N; Imura, M; Inukai, M; Satoh, H; Suzuki, T; Tomino, T, 2000) |
| "Milrinone therapy was associated with a rapid, well-sustained, and highly significant increase in cardiac index in all three dose groups (p less than 0." | 2.67 | Effects of variable dose milrinone in patients with low cardiac output after cardiac surgery. European Multicenter Trial Group. ( Feneck, RO, 1991) |
| "In non-hyperdynamic septic shock, CI, SVI, and DO₂ significantly increased while SVRI significantly decreased after milrinone when compared to placebo." | 2.47 | The role of milrinone in children with cardiovascular compromise: review of the literature. ( Abdul-Khaliq, H; Brown, K; Gortner, L; Meyer, S, 2011) |
| "Twenty-five infants had circulatory collapse during the first 72 hours." | 2.42 | Prevention of early sudden circulatory collapse after the Norwood operation. ( Adatia, IT; Ashburn, DA; Burkhart, HM; De Oliveira, NC; Holtby, HM; Khalid, F; Van Arsdell, GS; Williams, WG, 2004) |
| "Milrinone has been shown to be effective in the treatment of acute low output syndrome, and a loading bolus infusion of 50 micrograms kg-1 over 10 min causes an increase in cardiac index and a fall in pulmonary capillary wedge pressure." | 2.38 | Overview of the effects of intravenous milrinone in acute heart failure following surgery. ( Copp, MV; Feneck, RO; Hill, AJ, 1992) |
| "To model the dosing of milrinone in preterm infants for prevention of PLCS after surgical closure of patent ductus arteriosus (PDA)." | 1.46 | Dosing of Milrinone in Preterm Neonates to Prevent Postligation Cardiac Syndrome: Simulation Study Suggests Need for Bolus Infusion. ( Hallik, M; Metsvaht, T; Starkopf, J; Tasa, T, 2017) |
| "Tachyarrhythmias are common after the Norwood stage I palliation." | 1.40 | Tachyarrhythmias after the Norwood procedure: relationship and effect of vasoactive agents. ( Collins, KK; da Cruz, EM; Jaggers, J; Kaufman, J; McCanta, AC; McFerson, MC; Pan, Z, 2014) |
| "Diffuse cerebral vasospasm is a rare complication following tumour resection." | 1.40 | Diffuse cerebral vasospasm following resection of a hypoglossal schwannoma in a child. ( Afshari, FT; Fernandes, HM; Fitzgerald, JJ; Garnett, MR; Higgins, JN; Santarius, T, 2014) |
| "Secondary pulmonary hypertension is a frequent condition after heart valve surgery." | 1.36 | Combined usage of inhaled and intravenous milrinone in pulmonary hypertension after heart valve surgery. ( Bulat, C; Carev, M; Husedzinović, I; Jercić, A; Karanović, N; Letica, D; Lojpur, M; Marovih, Z; Nenadić, D, 2010) |
| "Milrinone is a phosphodiesterase 3 inhibitor that inhibits the breakdown of cyclic adenosine monophosphate and selectively relaxes smooth muscle." | 1.35 | Nebulized phosphodiesterase III inhibitor during warm ischemia attenuates pulmonary ischemia-reperfusion injury. ( Aoyama, A; Bando, T; Chen, F; Cui, Y; Date, H; Fujinaga, T; Okamoto, T; Sakai, H; Shoji, T; Zhang, J; Zhao, X, 2009) |
| "Their mitral regurgitation (MR) is a result of left ventricular (LV) geometrical distortion." | 1.33 | Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair. ( Bolling, SF; Geltz, A; Spoor, MT, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (18.60) | 18.2507 |
| 2000's | 15 (34.88) | 29.6817 |
| 2010's | 19 (44.19) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huh, J | 1 |
| Chung, H | 1 |
| Hwang, W | 1 |
| Ren, YS | 1 |
| Li, LF | 1 |
| Peng, T | 1 |
| Tan, YJ | 1 |
| Sun, Y | 1 |
| Cheng, GL | 1 |
| Zhang, GM | 1 |
| Li, J | 1 |
| Theodoraki, K | 1 |
| Thanopoulos, A | 1 |
| Rellia, P | 1 |
| Leontiadis, E | 1 |
| Zarkalis, D | 1 |
| Perreas, K | 1 |
| Antoniou, T | 1 |
| Hallik, M | 2 |
| Ilmoja, ML | 1 |
| Tasa, T | 2 |
| Standing, JF | 1 |
| Takkis, K | 1 |
| Veigure, R | 1 |
| Kipper, K | 1 |
| Jalas, T | 1 |
| Raidmäe, M | 1 |
| Uibo, K | 1 |
| Starkopf, J | 2 |
| Metsvaht, T | 2 |
| EL-Khuffash, A | 1 |
| McNamara, PJ | 1 |
| Lapointe, A | 1 |
| Jain, A | 1 |
| McFerson, MC | 1 |
| McCanta, AC | 1 |
| Pan, Z | 1 |
| Collins, KK | 1 |
| Jaggers, J | 1 |
| da Cruz, EM | 1 |
| Kaufman, J | 1 |
| Afshari, FT | 1 |
| Fitzgerald, JJ | 1 |
| Higgins, JN | 1 |
| Garnett, MR | 1 |
| Fernandes, HM | 1 |
| Santarius, T | 1 |
| Burkhardt, BE | 1 |
| Rücker, G | 1 |
| Stiller, B | 1 |
| Porhomayon, J | 1 |
| Davari-Farid, S | 1 |
| Li, CM | 1 |
| Arora, P | 1 |
| Pourafkari, L | 1 |
| Nader, ND | 1 |
| Mills, KI | 1 |
| Kaza, AK | 1 |
| Walsh, BK | 1 |
| Bond, HC | 1 |
| Ford, M | 1 |
| Wypij, D | 1 |
| Thiagarajan, RR | 1 |
| Almodovar, MC | 1 |
| Quinonez, LG | 1 |
| Baird, CW | 1 |
| Emani, SE | 1 |
| Pigula, FA | 1 |
| DiNardo, JA | 1 |
| Kheir, JN | 1 |
| Gebhard, CE | 1 |
| Desjardins, G | 1 |
| Gebhard, C | 1 |
| Gavra, P | 1 |
| Denault, AY | 1 |
| Vimala, S | 1 |
| Madhusudhan, S | 1 |
| Sahoo, BK | 1 |
| Fleming, GA | 1 |
| Murray, KT | 1 |
| Yu, C | 1 |
| Byrne, JG | 1 |
| Greelish, JP | 1 |
| Petracek, MR | 1 |
| Hoff, SJ | 1 |
| Ball, SK | 1 |
| Brown, NJ | 1 |
| Pretorius, M | 1 |
| Zhang, J | 1 |
| Chen, F | 1 |
| Zhao, X | 1 |
| Aoyama, A | 1 |
| Okamoto, T | 1 |
| Fujinaga, T | 1 |
| Shoji, T | 1 |
| Sakai, H | 1 |
| Cui, Y | 1 |
| Bando, T | 1 |
| Date, H | 1 |
| Axelsson, B | 1 |
| Arbeus, M | 1 |
| Magnuson, A | 1 |
| Hultman, J | 1 |
| Carev, M | 1 |
| Bulat, C | 1 |
| Karanović, N | 1 |
| Lojpur, M | 1 |
| Jercić, A | 1 |
| Nenadić, D | 1 |
| Marovih, Z | 1 |
| Husedzinović, I | 1 |
| Letica, D | 1 |
| Meyer, S | 1 |
| Gortner, L | 1 |
| Brown, K | 1 |
| Abdul-Khaliq, H | 1 |
| Vogt, W | 1 |
| Läer, S | 1 |
| Zangrillo, A | 1 |
| Biondi-Zoccai, G | 1 |
| Ponschab, M | 1 |
| Greco, M | 1 |
| Corno, L | 1 |
| Covello, RD | 1 |
| Cabrini, L | 1 |
| Bignami, E | 1 |
| Melisurgo, G | 1 |
| Landoni, G | 1 |
| Gong, M | 1 |
| Lin, XZ | 1 |
| Lu, GT | 1 |
| Zheng, LJ | 1 |
| Fan, Y | 1 |
| Zhang, AM | 1 |
| Weng, YG | 1 |
| Huebler, M | 1 |
| Miera, O | 1 |
| Franz, N | 1 |
| Qian, GS | 1 |
| Hetzer, R | 1 |
| Hoffman, TM | 1 |
| Bush, DM | 1 |
| Wernovsky, G | 1 |
| Cohen, MI | 1 |
| Wieand, TS | 1 |
| Gaynor, JW | 1 |
| Spray, TL | 1 |
| Rhodes, LA | 1 |
| Möllhoff, T | 1 |
| Schmidt, C | 1 |
| Van Aken, H | 1 |
| Berendes, E | 1 |
| Buerkle, H | 1 |
| Marmann, P | 1 |
| Reinbold, T | 1 |
| Prenger-Berninghoff, R | 1 |
| Tjan, TD | 1 |
| Scheld, HH | 1 |
| Deng, MC | 1 |
| Schuetz, A | 1 |
| Schulze, C | 1 |
| Wildhirt, SM | 1 |
| De Oliveira, NC | 1 |
| Ashburn, DA | 1 |
| Khalid, F | 1 |
| Burkhart, HM | 1 |
| Adatia, IT | 1 |
| Holtby, HM | 1 |
| Williams, WG | 1 |
| Van Arsdell, GS | 1 |
| Trachte, AL | 1 |
| Lobato, EB | 1 |
| Urdaneta, F | 1 |
| Hess, PJ | 1 |
| Klodell, CT | 1 |
| Martin, TD | 1 |
| Staples, ED | 1 |
| Beaver, TM | 1 |
| Spoor, MT | 1 |
| Geltz, A | 1 |
| Bolling, SF | 1 |
| Oztekin, I | 1 |
| Yazici, S | 1 |
| Oztekin, DS | 1 |
| Goksel, O | 1 |
| Issever, H | 1 |
| Canik, S | 1 |
| Rex, S | 1 |
| Schaelte, G | 1 |
| Metzelder, S | 1 |
| Flier, S | 1 |
| de Waal, EE | 1 |
| Autschbach, R | 1 |
| Rossaint, R | 1 |
| Buhre, W | 1 |
| Das, PA | 1 |
| Skoyles, JR | 1 |
| Sherry, KM | 1 |
| Peacock, JE | 1 |
| Fox, PA | 1 |
| Woolfrey, SG | 1 |
| McBride, WT | 1 |
| McMurray, TJ | 1 |
| Kochi, K | 1 |
| Kyo, S | 1 |
| Yokote, Y | 1 |
| Ueda, K | 1 |
| Asano, H | 1 |
| Koyanagi, T | 1 |
| Ohuchi, H | 1 |
| Omoto, R | 1 |
| Hayashida, N | 1 |
| Tomoeda, H | 1 |
| Oda, T | 1 |
| Tayama, E | 1 |
| Chihara, S | 1 |
| Kawara, T | 1 |
| Aoyagi, S | 1 |
| Chu, CC | 1 |
| Lin, SM | 1 |
| New, SH | 1 |
| Ting, CK | 1 |
| Chow, LH | 1 |
| Tsou, MY | 1 |
| Tsai, SK | 1 |
| Lee, TY | 1 |
| Canver, CC | 1 |
| Chanda, J | 1 |
| Hibino, N | 1 |
| Tomino, T | 1 |
| Satoh, H | 1 |
| Hamawaki, M | 1 |
| Imura, M | 1 |
| Suzuki, T | 1 |
| Inukai, M | 1 |
| Kikura, M | 1 |
| Sato, S | 1 |
| Ricksten, S | 1 |
| Harris, MN | 1 |
| Daborn, AK | 1 |
| O'Dwyer, JP | 1 |
| George, M | 1 |
| Lehot, JJ | 1 |
| Estanove, S | 1 |
| Copp, MV | 1 |
| Hill, AJ | 1 |
| Feneck, RO | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Levosimendan Administration in High Risk Cardiac Surgery Patients With Pulmonary Hypertension[NCT04599816] | 45 participants (Actual) | Interventional | 2020-10-17 | Completed | |||
| Comparison of Intravenous Levosimendan and Inhalational Milrinone in High Risk Cardiac Patients With Pulmonary Hypertension[NCT04718350] | 40 participants (Anticipated) | Interventional | 2021-01-27 | Recruiting | |||
| Oxygen Consumption-based Assessments of Hemodynamics in Neonates Following Congenital Heart Surgery (Oxy-CAHN Study)[NCT02184169] | 27 participants (Actual) | Interventional | 2012-12-31 | Completed | |||
| Validation of Cerebral Non-invasive Monitoring and Prediction of Post-operative Delirium and Outcomes: A Prospective Observational Study[NCT04643834] | 151 participants (Anticipated) | Observational | 2019-11-21 | Recruiting | |||
| RAAS, Inflammation, and Post-operative AF[NCT00141778] | Phase 2/Phase 3 | 455 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Multicenter Study for the Prevention of Post-Operative Cardiac Arrhythmias[NCT04234906] | Phase 4 | 870 participants (Anticipated) | Interventional | 2023-01-31 | Not yet recruiting | ||
| Right Ventricular Function After Withdrawal of Phosphodiesterase-5 Inhibitors in Left Ventricular Assist Device Recipients[NCT04117659] | 32 participants (Actual) | Interventional | 2019-10-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A calculated estimate of cardiac index/systemic blood flow based on the Fick principle. (NCT02184169)
Timeframe: While mechanically ventilated, up to 14 days
| Intervention | L/min/m2 (Mean) |
|---|---|
| Hypoplastic Left Heart Syndrome | 1.3 |
| Transposition of the Great Arteries | 2.2 |
Oxygen consumption is the mass of oxygen gas consumed per minute, measured as the difference between oxygen mass inspired versus exhaled per minute. (NCT02184169)
Timeframe: While mechanically ventilated, up to 14 days
| Intervention | mL oxygen/min/m^2 (Mean) |
|---|---|
| HLHS | 72 |
| TGA With/Without VSD | 102 |
Percentage of patients with a creatinine concentrations >2.5mg/dl (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average, depending on the study group.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 5.4 |
| Ramipril | 0.7 |
| Spironolactone | 0.7 |
The percentage of patients in each study arm who died. (NCT00141778)
Timeframe: Measured until the time of hospital discharge
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 1.4 |
| Ramipril | 2.0 |
| Spironolactone | 0 |
Percentage of patients who had a serum potassium concentrations <3.5 milliequivalents (mEq)/L (NCT00141778)
Timeframe: Measured until the time of hospital discharge, which was an average of 5.7 to 6.8 days depending on the treatment arm.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 11.6 |
| Ramipril | 13.8 |
| Spironolactone | 6.8 |
Percentage of patients with hypotension defined as a systolic blood pressure <90 mmHg and/or prolonged requirement for vasopressor use. (NCT00141778)
Timeframe: Measured during and after surgery, until discharge, from 5.7 to 6.8 days on average.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 5.4 |
| Ramipril | 10.6 |
| Spironolactone | 10.2 |
(NCT00141778)
Timeframe: Measured from the day of surgery until the time of hospital discharge
| Intervention | days (Mean) |
|---|---|
| Placebo | 6.8 |
| Ramipril | 5.7 |
| Spironolactone | 5.8 |
The primary endpoint of the study was the percentage of patients with electrocardiographically confirmed AF of at least 10 secs duration at any time following the end of surgery until hospital discharge, an average from 5.7 days in the ramipril group to 6.8 days in the placebo group. Patients were monitored continuously on telemetry throughout the postoperative period until discharge. Electrocardiograms were obtained for any rhythm changes detected on telemetry monitoring, and in addition, electrocardiograms were performed preoperatively, at admission to the intensive care unit, and daily starting on postoperative day 1. All electrocardiograms and rhythm strips were reviewed in a blinded fashion by a single cardiac electrophysiologist. (NCT00141778)
Timeframe: Measured from admission to the ICU until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 27.2 |
| Ramipril | 27.8 |
| Spironolactone | 25.9 |
Percentage of patients in each study group who experience a cerebrovascular event, confirmed by CT. (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average depending on the study arm.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 2.7 |
| Ramipril | 1.3 |
| Spironolactone | 2.0 |
It is the time in minutes that it took to extubate the patient after surgery. (NCT00141778)
Timeframe: It is the time (in minutes) from admission to the ICU until tracheal extubation
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 1091.3 |
| Ramipril | 970.1 |
| Spironolactone | 576.4 |
C-reactive protein was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period
| Intervention | ug/mL (Mean) | ||||
|---|---|---|---|---|---|
| Initiation of surgery | Postoperative day 1 | Postoperative day 2 | Postoperative day 3 | Postoperative day 4 | |
| Placebo | 4.1 | 51.4 | 134.8 | 128.3 | 94.1 |
| Ramipril | 4.3 | 49.9 | 131.0 | 164.8 | 105.2 |
| Spironolactone | 3.9 | 64.3 | 127.8 | 189.4 | 126.5 |
Interleukin-6 was measured at several time points (see time points in table) over the course of the study (NCT00141778)
Timeframe: Perioperative period
| Intervention | pg/ml (Mean) | |||||
|---|---|---|---|---|---|---|
| Initiation of surgery | 30min intraop | 60min intraop | Postop | Postoperative day 1 | Postoperative day 2 | |
| Placebo | 4.7 | 12.0 | 15.6 | 130.0 | 119.0 | 100.3 |
| Ramipril | 4.6 | 20.5 | 28.8 | 202.1 | 171.0 | 95.5 |
| Spironolactone | 6.6 | 11.3 | 17.4 | 145.7 | 164.9 | 109.6 |
Plasminogen activator inhibitor-1 (PAI-1) was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period
| Intervention | ng/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| Initiation of surgery | 30min intraop | 60min intraop | Postop | Postoperative day 1 | Postoperative day 2 | |
| Placebo | 19.6 | 19.2 | 21.0 | 36.4 | 55.2 | 28.1 |
| Ramipril | 16.2 | 19.7 | 22.0 | 38.9 | 47.9 | 25.7 |
| Spironolactone | 17.3 | 17.3 | 20.1 | 34.0 | 48.9 | 31.0 |
9 reviews available for milrinone and Postoperative Complications
| Article | Year |
|---|---|
The effect of milrinone on mortality in adult patients who underwent CABG surgery: a systematic review of randomized clinical trials with a meta-analysis and trial sequential analysis.
Topics: Adult; Aged; Cardiovascular Agents; Coronary Artery Bypass; Coronary Artery Disease; Female; Humans; | 2020 |
Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease.
Topics: Cardiac Output, Low; Cardiotonic Agents; Dobutamine; Heart Defects, Congenital; Humans; Hydrazones; | 2015 |
The role of milrinone in children with cardiovascular compromise: review of the literature.
Topics: Administration, Inhalation; Adolescent; Cardiac Output, Low; Cardiotonic Agents; Child; Child, Presc | 2011 |
Milrinone and mortality in adult cardiac surgery: a meta-analysis.
Topics: Adult; Cardiac Surgical Procedures; Humans; Milrinone; Postoperative Complications; Randomized Contr | 2012 |
Off-pump epicardial tissue sealing--a novel method for atrioventricular disruption complicating mitral valve procedures.
Topics: Aged; Aortic Valve; Aprotinin; Blood Loss, Surgical; Cardiac Tamponade; Cardiopulmonary Bypass; Drug | 2004 |
Prevention of early sudden circulatory collapse after the Norwood operation.
Topics: Adrenergic alpha-Antagonists; Biomarkers; Cardiopulmonary Bypass; Cardiotonic Agents; Case Managemen | 2004 |
Oral sildenafil reduces pulmonary hypertension after cardiac surgery.
Topics: Adult; Aged; Cardiac Surgical Procedures; Drug Evaluation; Drug Resistance; Female; Hemodynamics; Hu | 2005 |
[The pulmonary vasodilatory effect of inhaled prostacyclin and milrinone in heart].
Topics: Acute Disease; Administration, Inhalation; Cardiac Surgical Procedures; Cyclic AMP; Drug Synergism; | 2001 |
Overview of the effects of intravenous milrinone in acute heart failure following surgery.
Topics: Cardiac Output; Cardiac Output, Low; Cardiac Surgical Procedures; Humans; Infusions, Intravenous; Mi | 1992 |
13 trials available for milrinone and Postoperative Complications
| Article | Year |
|---|---|
Comparison of the Effects of Milrinone, Sodium Nitroprusside, and Nitroglycerine for Induced Hypotension in Elderly Patients Undergoing Spine Surgery: A Randomized Controlled Trial.
Topics: Aged; Blood Loss, Surgical; Double-Blind Method; Female; Humans; Hypotension, Controlled; Male; Milr | 2019 |
Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery.
Topics: Adult; Aged; Atrial Fibrillation; Cardiac Surgical Procedures; Cardiotonic Agents; Coronary Disease; | 2008 |
Milrinone improves diastolic function in coronary artery bypass surgery as assessed by acoustic quantification and peak filling rate: a prospective randomized study.
Topics: Acoustics; Aged; Coronary Artery Bypass; Diastole; Double-Blind Method; Echocardiography, Transesoph | 2010 |
Preoperative inhalation of milrinone attenuates inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass.
Topics: Administration, Inhalation; Analysis of Variance; Cardiopulmonary Bypass; Cytokines; Female; Hemodyn | 2012 |
Myocardial ischaemia in patients with impaired left ventricular function undergoing coronary artery bypass grafting--milrinone versus nifedipin.
Topics: Aged; Anesthesia, General; Calcium Channel Blockers; Coronary Artery Bypass; Coronary Disease; Creat | 2002 |
Effects of low-dose milrinone on weaning from cardiopulmonary bypass and after in patients with mitral stenosis and pulmonary hypertension.
Topics: Adult; Cardiopulmonary Bypass; Female; Heart Valve Prosthesis Implantation; Humans; Hypertension, Pu | 2007 |
Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial.
Topics: Administration, Inhalation; Aged; Cardiac Output, Low; Cardiopulmonary Bypass; Catheterization, Swan | 2008 |
Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass.
Topics: Aged; Coronary Artery Bypass; Creatine Kinase; Cyclic AMP; Cytokines; Female; Hemodynamics; Humans; | 1999 |
[The effect of milrinone administrated before weaning from cardiopulmonary bypass in adult cardiac surgery].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Cardiopulmonary Bypass; Cyclic Nucleotide Phosphod | 2000 |
The efficacy of preemptive Milrinone or Amrinone therapy in patients undergoing coronary artery bypass grafting.
Topics: Aged; Amrinone; Cardiotonic Agents; Coronary Artery Bypass; Dopamine; Double-Blind Method; Echocardi | 2002 |
Milrinone and the pulmonary vascular system.
Topics: Adult; Cardiac Surgical Procedures; Heart Failure; Humans; Milrinone; Phosphodiesterase Inhibitors; | 1992 |
Haemodynamic and biological effects of intravenous milrinone in patients with a low cardiac output syndrome following cardiac surgery: multicentre study.
Topics: Adult; Cardiac Output, Low; Cardiac Surgical Procedures; Hemodynamics; Humans; Infusions, Intravenou | 1992 |
Effects of variable dose milrinone in patients with low cardiac output after cardiac surgery. European Multicenter Trial Group.
Topics: Cardiac Output; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Drug Evaluatio | 1991 |
21 other studies available for milrinone and Postoperative Complications
| Article | Year |
|---|---|
A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Arterial Pressure; Cardiopulmonary Bypass; Dose | 2017 |
A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Arterial Pressure; Cardiopulmonary Bypass; Dose | 2017 |
A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Arterial Pressure; Cardiopulmonary Bypass; Dose | 2017 |
A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Arterial Pressure; Cardiopulmonary Bypass; Dose | 2017 |
Population Pharmacokinetics and Dosing of Milrinone After Patent Ductus Arteriosus Ligation in Preterm Infants.
Topics: Cardiotonic Agents; Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Hypotension; Infant | 2019 |
Adrenal function in preterm infants undergoing patent ductus arteriosus ligation.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Cardiotonic Agents; Cohort Studies; Ductus Arter | 2013 |
Tachyarrhythmias after the Norwood procedure: relationship and effect of vasoactive agents.
Topics: Colorado; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heart Ra | 2014 |
Diffuse cerebral vasospasm following resection of a hypoglossal schwannoma in a child.
Topics: Cerebral Angiography; Child; Cranial Nerve Neoplasms; Female; Humans; Milrinone; Neurilemmoma; Nimod | 2014 |
Intraoperative administration of vasopressin during coronary artery bypass surgery is associated with acute postoperative kidney injury.
Topics: Acute Kidney Injury; Arginine Vasopressin; Cardiopulmonary Bypass; Case-Control Studies; Coronary Ar | 2015 |
Dosing of Milrinone in Preterm Neonates to Prevent Postligation Cardiac Syndrome: Simulation Study Suggests Need for Bolus Infusion.
Topics: Cardiac Output; Cardiotonic Agents; Ductus Arteriosus, Patent; Estonia; Female; Gestational Age; Hum | 2017 |
Phosphodiesterase Inhibitor-Based Vasodilation Improves Oxygen Delivery and Clinical Outcomes Following Stage 1 Palliation.
Topics: Blalock-Taussig Procedure; Cardiopulmonary Resuscitation; Extracorporeal Membrane Oxygenation; Femal | 2016 |
Intratracheal Milrinone Bolus Administration During Acute Right Ventricular Dysfunction After Cardiopulmonary Bypass.
Topics: Aged; Cardiopulmonary Bypass; Cardiotonic Agents; Cohort Studies; Female; Humans; Intubation, Intrat | 2017 |
Life-threatening Tachyarrhythmia Following Intra-Arterial Milrinone for Cerebral Vasospasm.
Topics: Adult; Electrocardiography; Humans; Male; Milrinone; Postoperative Complications; Subarachnoid Hemor | 2018 |
Nebulized phosphodiesterase III inhibitor during warm ischemia attenuates pulmonary ischemia-reperfusion injury.
Topics: Aerosols; Animals; DNA Nucleotidylexotransferase; In Situ Nick-End Labeling; Lung; Lung Transplantat | 2009 |
Combined usage of inhaled and intravenous milrinone in pulmonary hypertension after heart valve surgery.
Topics: Administration, Inhalation; Aortic Valve; Female; Heart Valve Prosthesis Implantation; Humans; Hyper | 2010 |
Drug use patterns for the prevention of paediatric low cardiac output syndrome in Europe.
Topics: Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Child; Europe; Health Care Sur | 2011 |
Factors associated with the need of biventricular mechanical circulatory support in children with advanced heart failure.
Topics: Adolescent; Cardiac Surgical Procedures; Child; Child, Preschool; Female; Heart Failure; Heart-Assis | 2013 |
Postoperative junctional ectopic tachycardia in children: incidence, risk factors, and treatment.
Topics: Amiodarone; Cardiac Pacing, Artificial; Child; Child, Preschool; Dopamine; Female; Heart Defects, Co | 2002 |
Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathy, Dilated; Combined Modality | 2006 |
Disposition of milrinone in patients after cardiac surgery.
Topics: Adult; Aged; Aged, 80 and over; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiopulmonary By | 1994 |
Prolonged high frequency jet ventilation and milrinone therapy following modified Fontan procedure.
Topics: Cardiotonic Agents; Child; Heart Atria; Heart Defects, Congenital; High-Frequency Jet Ventilation; H | 1994 |
[The effect of milrinone for the shock patients after cardiac surgery].
Topics: Aged; Cardiac Surgical Procedures; Cardiotonic Agents; Coronary Artery Bypass; Female; Heart Valve P | 1999 |
Effect of milrinone on postbypass pulmonary hypertension in children after tetralogy of Fallot repair.
Topics: Adolescent; Adult; Cardiopulmonary Bypass; Child; Child, Preschool; Female; Humans; Hypertension, Pu | 2000 |
Milrinone for long-term pharmacologic support of the status 1 heart transplant candidates.
Topics: Adult; Aged; Cardiotonic Agents; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Infusio | 2000 |